Please login to the form below
opioids
This page shows the latest opioids news and features for those working in and with pharma, biotech and healthcare.
AcelRX’s potent opioid tablets set to win FDA backing for pain relief
AcelRX’ s potent opioid tablets set to win FDA backing for pain relief. ... Unlike intravenous-based opioids, Dsuvia, which is already approved in the EU, could allow for a more effective and less invasive pain reliever.
Latest news
-
Janssen submits esketamine in Europe for treatment resistant depression
However analysts at Evaluate say concerns that the drug might activate opioid receptors in the brain – and therefore be an addiction risk – could lead to the FDA imposing warnings or restrictions
-
FDA awards another non-opioid pain drug breakthrough status
FDA awards another non-opioid pain drug breakthrough status. Second drug fast-tracked amid addiction epidemic. ... prevent more people becoming addicted to opioid painkillers after having been prescribed them by doctors.
-
Regeneron and Teva close gap on rivals with NGF pain drug
therapeutic choices to treat their chronic pain, other than with non-steroidal anti-inflammatory drugs or opioids," said Yancopolous. ... In contrast to opioids, which alter pain perception by targeting opioid receptors, NGF inhibitors block signalling
-
Indivior push to diversify boosted by schizophrenia drug approval
For years, Indivior has made the bulk of its revenues from opioid addiction treatment Suboxone.
-
Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
We are encouraged by these results, which speak to the potential of tanezumab as a non-opioid treatment option for pain reduction and improvement in physical function in people living with
More from news
Approximately 14 fully matching, plus 128 partially matching documents found.
Latest Intelligence
-
Pharma deals continue to slide
Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen (J&J) and Xoma has licensed its interleukin 1 beta intellectual property for cardiovascular disease to Novartis plus ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset
-
Grünenthal's relentless pursuit of relief
It has the potential to reduce pain without typical opioid therapy side effects and is in development for topical application in hypersensitivity disorders such as Bladder Pain Syndrome or Chronic Stump
-
How digital content helps HCPs curb opioid abuse through better prescribing decisions
In fact, a poll of physicians within our digital community found that 64% believe that doctors have a responsibility to help curb opioid abuse. ... And by delivering information concisely and in an engaging format, this approach is having a measurable
-
Deal Watch March 2016
$110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.
-
Pharma deals in September 2015
Zalviso is a combination drug and device product which uses a patient controlled dispenser to deliver a sub-lingual formulation of sufentanil, an opioid with a high therapeutic index.
More from intelligence
Approximately 1 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Egalet appoints Stan Musial as CFO
s pipeline of abuse-deterrent opioids are nearing phase III.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report.
-
IOTOD: Improving Opioid Dependence Outcomes
IOTOD: Improving Opioid Dependence Outcomes.
-
How digital content is helping physicians curb the opioid abuse epidemic
using their state’ s Prescription Drug Monitoring Program (PDMP) database before prescribing opioids to a patient. ... topic. And there’ s plenty of evidence that this approach works— having a measurable and almost immediate impact on how
-
"Legal highs" ruling leaves illegal labs laughing
So we are acutely aware of the devastation caused by the opioid epidemic in the US, and the criticism aimed at Purdue, the maker of OxyContin. ... We have also pitched for agents designed to treat opioid overdose and alcohol abuse.
-
"Legal highs" ruling leaves illegal labs laughing
So we are acutely aware of the devastation caused by the opioid epidemic in the US, and the criticism aimed at Purdue, the maker of OxyContin. ... We have also pitched for agents designed to treat opioid overdose and alcohol abuse.
More from PMHub
Approximately 2 fully matching, plus 7 partially matching documents found.
Featured jobs
- Account Director – Global Healthcare PR
-
Salary TBC
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
-
Scientific Director
-
Highly Competitive Salary &Benefits
-
Associate Medical Director
-
Salary TBC
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
-
Account Director - Digital
-
Great salary and benefits
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Account Director
-
Negotiable
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Scientific Team Lead
-
Competitive Salary
- Director Healthcare PR Communications
-
Salary TBC
- Experienced Editor, London, Medical Communications
-
Competitive package
Subscribe to our email news alerts
PMHub
Grace Communications
Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....
Latest intelligence
- Making Europe a leader in bioscience: boosting trust and opening minds
- A vision of Paris as Europe’s leading hub for life sciences innovation...
- Tackling a formidable foe
- Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
- Cancer care – the power of new technologies
- With patient numbers set to soar, how can we make a difference?...
Quick links
Infographics
